A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides

Archives of Ophthalmology

Volumn 126, Issue 5, 2008, Pages 626-631

  Albert, Daniel M ^a   Gangnon, Ronald E ^a   Grossniklaus, Hans E ^b   Green, W Richard ^c   Darjatmoko, Soesiawati ^a   Kulkarni, Amol D ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST;

ADVENTITIA; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DESCEMET MEMBRANE; EYE COLOR; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; IRIDECTOMY; MAJOR CLINICAL STUDY; MELANOCYTE; NUCLEOLUS; PIGMENT EPITHELIUM; PIGMENTATION; PRIORITY JOURNAL; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ANTIHYPERTENSIVE AGENTS; ENDOTHELIUM, VASCULAR; FIBROBLASTS; GLAUCOMA; HUMANS; IRIDECTOMY; IRIS; IRIS DISEASES; MELANINS; MELANOCYTES; MELANOSIS; PROSTAGLANDINS F, SYNTHETIC;

EID: 43549086687     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.126.5.626     Document Type: Article

References (37)

1. Nguyen QH. The role of prostaglandin analogues in the treatment of glaucoma in the 21st century. Int Ophthalmol Clin. 2004;44(2):15-27.
2. Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6(1):45-52.
3. Albert DM, Gangnon RE, Zimbric ML, et al. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients. Arch Ophthalmol. 2004;122(11):1680-1685.
4. Arranz-Marquez E, Teus MA, Saornil MA, Mendez MC, Gil R. Analysis of irises with a latanoprost-induced change in iris color. Am J Ophthalmol. 2004;138(4):625-630.
5. Cracknell KP, Grierson I, Hogg P. Morphometric effects of long-term exposure to latanoprost. Ophthalmology. 2007;114(5):938-948.
6. Wilkerson CL, Syed NS, Fisher MR, Robinson NL, Wallow IH, Albert DM. Melanocytes and iris color: light microscopic findings. Arch Ophthalmol. 1996;114(4):437-442.
7. Imesch PD, Bindley CD, Khademian Z, et al. Melanocytes and iris color: electron microscopic findings. Arch Ophthalmol. 1996;114(4):443-447.
8. Albert DM, Green WR, Zimbric ML, et al. Iris melanocyte numbers in Asian, African-American, and Caucasian irides. Trans Am Ophthalmol Soc. 2003;101:217-222.
9. Eagle RC Jr. Iris pigmentation and pigmented lesions: an ultrastructural study. Trans Am Ophthalmol Soc. 1988;86:581-687.
10. Imesch PD, Wallow IH, Albert DM. The color of the human eye: a review of the morphologic correlates and of some conditions that affect iridial pigmentation. Surv Ophthalmol. 1997;41(suppl 2):S117-S123.
11. Grierson I, Cracknell KP, Pfeiffer N. The iris after prostanoid treatment. Curr Opin Ophthalmol. 2001;12(2):112-118.
12. Yanoff M, Fine BS. Ocular Pathology: A Text and Atlas. 2nd ed. Philadelphia, PA: Harper & Row Publishers; 1982:822.
13. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41(suppl 2):S129-S138.
14. Camras CB, Wax MB, Ritch R, et al; United States Latanoprost Study Group. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. Am J Ophthalmol. 1998;126(3):390-399.
15. Teus MA, Arranz-Marquez E, Lucea-Suescun P. Incidence of iris colour change in latanoprost treated eyes. Br J Ophthalmol. 2002;86(10):1085- 1088.
16. Arranz-Marquez E, Teus MA. Effect of age on the development of a latanoprost-induced increase in iris pigmentation. Ophthalmology. 2007;114(7):1255-1258.
17. Stjernschantz JW, Albert DM, Hu D, Drago F, Wistrand PJ. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol. 2002;47(suppl 1):S162-S175.
18. Grierson I, Pfeiffer N, Cracknell KP, Appleton P. Histology and fine structure of the iris and outflow system following latanoprost therapy. Surv Ophthalmol. 2002;47(suppl 1):S176-S184.
19. Grierson I, Lee WR, Albert DM. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change. Arch Ophthalmol. 1999;117(3):394-396.
20. Tsai JC, Sivak-Callcott JA, Haik BG, Zhang J, McLean IW. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report. J Glaucoma. 2001;10(5):411-413.
21. Pfeiffer N, Grierson I, Goldsmith H, Hochgesand D, Winkgen-Bohres A, Appleton P. Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 Study. Arch Ophthalmol. 2001;119(2):191-196.
22. Lindsey JD, Jones HL, Hewitt EG, Angert M, Weinreb RN. Induction of tyrosinase gene transcription in human iris organ cultures exposed to latanoprost. Arch Ophthalmol. 2001;119(6):853-860.
23. Drago F, Marino A, La Manna C. Alpha-methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro. Exp Eye Res. 1999;68(1):85-90.
24. Stjernschantz J, Ocklind A, Wentzel P, Lake S, Hu DN. Latanoprost-induced increase of tyrosinase transcription in iridial melanocytes. Acta Ophthalmol Scand. 2000;78(6):618-622.
25. Dutkiewicz R, Albert DM, Levin LA. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res. 2000;70(5):563-569.
26. 2α and latanoprost on cultured human iridial melanocytes. Exp Eye Res. 2000;70(1):113-120.
27. Lindquist NG, Larsson BS, Stjernschantz J. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue. Exp Eye Res. 1999;69(4):431-436.
28. Selén G, Stjernschantz J, Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol. 1997;41(suppl 2):S125-S128.
29. Prota G, Vincensi MR, Mapolitano A, Selen G, Stjernschantz J. Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys. Pigment Cell Res. 2000;13(3):147-150.
30. Zhan GL, Toris CB, Camras CB, Wang YL, Bito LZ. Prostaglandin-induced iris color darkening: an experimental model. Arch Ophthalmol. 1998;116(8):1065-1068.
31. De Asua LJ, Clingan D, Rudland PS. Initiation of cell proliferation in culture mouse fibroblasts by prostaglandin F2alpha. Proc Natl Acad Sci U S A. 1975;72(7):2724-2728.
32. Black FM, Wakelam MJ. Activation of inositol phospholipid breakdown by prostaglandin F2 alpha without any stimulation of proliferation in quiescent NIH-3T3 fibroblasts. Biochem J. 1990;266(3):661-667.
33. Conconi MT, Spinazzi R, Tommasini M, Limoli A, Parnigotto PP. Prostaglandin F2 alpha can modulate the growth and the differentiation of bovine corneal epithelial cells cultured in vitro. Ann Anat. 2001;183(6):567-573.
34. Alm A, Widengård I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand. 2000;78(1):71-76.
35. Latanoprost-Induced Iris Pigmentation Study Group. Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes. Jpn J Ophthalmol. 2006;50(2):96-99.
36. Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004;122(7):957-965.
37. Friström B, Nilsson SE. A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension. Br J Ophthalmol. 1997;81(10):867-870.